




# **THERASPHERE**<sup>™</sup> Y-90 Glass Microspheres | **Key Notable Trials**

TheraSphere is a proven minimally invasive transarterial radiation therapy that delivers high-dose radiation directly to the tumor that yields strong local tumor control and prolongs survival without limiting hepatocellular carcinoma (HCC) patient's eligibility for future treatment.

# STUDIED ACROSS MULTIPLE BCLC STAGES:

TheraSphere has been studied across a wide range of BCLC stages examining a variety of patients and disease characteristics. BCLC algorithm adapted to show patient population from key notable trials.



# **KEY TRIAL DESIGN AND BASELINE CHARACTERISTICS:**

	LEGACY	DOSISPHERE-01	TARGET	
Trial Design	Multi-center, U.S.	Multi-center, France	Multi-center, Global	
	Retrospective	Prospective, randomized	Retrospective	
	Single lesion	Single or multifocal† disease	Single or multifocal† disease	
	N=169	N=60	N=209	
Baseline Characteristics	BCLC: A, C	BCLC: B, C	BCLC: A,B,C	
	BCLC C: <b>39.5%</b>	BCLC C: 87%*	BCLC C: <b>54.5</b> %	
	PVT presence <sup>†</sup> : <b>0</b> %	PVT presence <sup>†</sup> : <b>65</b> %*	PVT presence <sup>†</sup> : <b>33.0</b> %	
	Lesion size: Median <b>2.6 cm</b> (range: 0.9-8.1)	Index lesion: Mean±SD <b>10.6* cm</b> ±2.8	Target lesion**: ≥ 3 to < 5 cm: 19.6% ≥ 5 to < 8 cm: 34.4% ≥ 8 cm: 45.9%  Median 7.3 cm (range 3.1-17.4)	
	Follow up: Median <b>29.9 M</b> (by reverse KM)	Follow up: Median <b>28.2 M</b>	Follow up: Median 13.1 M (short term focus based on imaging availability)	

<sup>\*</sup>in multicompartmental study arm, ITT population

<sup>\*\*</sup>target lesion with longest diameter using RECIST 1.1

<sup>†</sup>The safety and efficacy of TheraSphere in treatment of patients with PVT and/or multifocal disease has not been established

# **THERASPHERE**<sup>™</sup> Y-90 Glass Microspheres | **Key Notable Trials**

#### SAFE. TOLERABLE.

TheraSphere demonstrated a consistent safety profile with patients well-tolerating the treatment.

LEGACY		DOSISPHERE-01		TARGET	
5.6%	Low rates of device/procedure-related SAE's	8.6%	Low rate of patients experiencing ≥1 AE* (≥Grade 3) of personalized dosimetry approach (vs. 14.3% of standard dosimetry)	4.8%	of patients experienced ≥ Grade 3 hyperbilirubinemia in the absence of disease progression
3.1%	Low GI Disorders (abdominal pain, nausea, vomiting)				
0%	Patients experienced radiation-induced liver disease or failure				

<sup>\*</sup>Liver AE related to Y-90

#### PREDICTABLE HIGH EFFICACY

TheraSphere showed strong local tumor control and a correlation of high absorbed radiation dose-to-survival outcomes.

	LEGACY	DOSISPHERE-01	TARGET
ORR in Target Lesion	88% best response (mRECIST)	PDA: 71.4% (EASL at 3 months)* SDA: 35.7% (EASL at 3 months)	70.8% best response (mRECIST)
Overall Survival	83.5% OS rate at 3 years (TheraSphere as primary treatment) 93.0% OS rate at 3 years (TheraSphere followed by transplant or resection)	PDA: 26.6 M** SDA: 10.7 M	20.3 months When TAD >300 Gy, OS was 36.7 months, 200 to <300 Gy, OS was 25.1 months, <200 to Gy, OS was 16.1 months

PDA: Personalized dosimetry arm | SDA: Standardized dosimetry arm | TAD: Tumor absorbed dose

#### TheraSphere, through its robust clinical trials data across a wide spectrum of HCC patients demonstrates:

- The role of minimally invasive transarterial radiation therapy that is well-tolerated by the patient.
- Ability to deliver high-dose radiation directly to the tumor yielding a strong local tumor control and prolongs survival.
- Maintains patient's eligibility for future treatment while providing strong efficacy.
- 1. Reig M et al., BCLC strategy for prognosis prediction and treatment recommendation Barcelona Clinic Liver Cancer (BCLC) staging system. The 2022 update Journal of Hepatology (2021), doi: https://doi.org/10.1016/j.jhep.2021.11.018.
- 2. Salem R, Johnson GE, Kim E, Riaz A, Bishay V, Boucher E, Fowers K, Lewandowski R, Padia SA. Yttrium-90 Radioembolization for the Treatment of Solitary, Unresectable Hepatocellular Carcinoma: The LEGACY Study. Hepatology. 2021 Mar 19. doi: 10.1002/hep. 31819.
- 3. Lam, Marnix. A Global Study of Advanced Dosimetry in the Treatment of Hepatocellular Carcinoma with Yttrium-90 Glass Microspheres: Analyses from the TARGET Study. Presented at SIR. March 25, 2021
- 4. Garin E, Tselikas L, Guiu B et al. Personalized versus standard dosimetry approach of selective internal radiation therapy inpatients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial. Lancet Gastroenterol Hepatol. 2021, 6: 17-29

#### TheraSphere™ Yttrium-90 Glass Microspheres

INDICATION FOR USE: TheseSpheres is indicated for use as selective internal radiation therapy (SIRT) for local tumor control of socilarly tumors (1-8 cm in diameter), in patients with unresectable hepatocellular acrianoma (HCI, Oli-14). Pupit Sore a circular internals, well-companied liver function, no macrosaccular invasion, and good performance status. CoMTRAINDICATIONS: TheraSphere is contraindicated in patients: whose 1c-99m macrosaggregated albumin (MAA) hepatic arterial perfusion scintigraphy shows any deposition to the gastrointestinal tract that may not be corrected by angiographic techniques \*\* who show shurting of blood to the lungs that could result in delivery of greater than 16.5 million (10.61 GBq) of Y\*9 0 to the lungs. Radiation pneumonilish so thee misers received by an arterial perfusion scintigraphy shows any deposition to the lungs. Radiation pneumonilish so the earner than the patient of the patient expenditum of the companies of the patients received by a support of the patients received by a support of the patients received properties of the patients received properties of the patients received properties of the patients of t



### Peripheral Interventions

300 Boston Scientific Way Marlborough, MA 01752-1234 www.bostonscientific.com

To order product or for more information contact customer service at 1.888.272.1001.

© 2022 Boston Scientific Corporation or its affiliates. All rights reserved.

PI-1139306-AB

<sup>\*</sup>target lesion with longest diameter using RECIST 1.1

<sup>\*\*</sup>in multicompartmental study arm, ITT population